Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Zydus Lifesciences Yönetim
Yönetim kriter kontrolleri 3/4
Zydus Lifesciences' CEO'su Sharvil Patel, Apr2017 tarihinde atandı, in görev süresi 7.5 yıldır. in toplam yıllık tazminatı ₹ 300.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 60% maaş ve 40% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.001% ine doğrudan sahiptir ve bu hisseler ₹ 15.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 7.3 yıldır.
Anahtar bilgiler
Sharvil Patel
İcra Kurulu Başkanı
₹300.0m
Toplam tazminat
| CEO maaş yüzdesi | 60.0% |
| CEO görev süresi | 7.5yrs |
| CEO sahipliği | 0.001% |
| Yönetim ortalama görev süresi | 6.5yrs |
| Yönetim Kurulu ortalama görev süresi | 7.3yrs |
Son yönetim güncellemeleri
Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹42b |
| Mar 31 2024 | ₹300m | ₹180m | ₹38b |
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Tazminat ve Piyasa: Sharvil 'nin toplam tazminatı ($USD 3.57M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.09M ).
Tazminat ve Kazançlar: Sharvil 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Sharvil Patel (45 yo)
7.5yrs
Görev süresi
₹300,000,000
Tazminat
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Executive Director | 7.5yrs | ₹300.00m | 0.0015% ₹ 15.6m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 368.1m | |
| President & CEO of America | less than a year | Veri yok | Veri yok | |
| Chief Financial Officer | no data | ₹54.31m | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Company Secretary & Compliance Officer | 5.7yrs | ₹2.09m | Veri yok |
6.5yrs
Ortalama Görev Süresi
Deneyimli Yönetim: ZYDUSLIFE 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Executive Director | 27.2yrs | ₹300.00m | 0.0015% ₹ 15.6m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 368.1m | |
| Non-Executive Chairman | 29.4yrs | ₹1.20m | 74.98% ₹ 797.7b | |
| Independent Director | 8.4yrs | ₹4.00m | Veri yok | |
| Non-Executive Non-Independent Director | 27.2yrs | ₹4.00m | 0.0012% ₹ 12.3m | |
| Independent Non-Executive Director | 5.8yrs | ₹4.10m | Veri yok | |
| Independent Director | 1.9yrs | ₹3.50m | Veri yok | |
| Independent Director | 1.9yrs | ₹3.50m | Veri yok | |
| Independent Director | less than a year | Veri yok | 0.00044% ₹ 4.7m |
7.3yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ZYDUSLIFE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).